Tepotinib Hepatic Impairment Trial

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

The study investigated the effect of various degrees of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of tepotinib.

Key facts

Study ID
NCT03546608
Run by
EMD Serono Research & Development Institute, Inc.
People needed
18
Starts
2018-06-13
Expected to finish
2019-02-05
Last updated by the study team
2024-08-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.